# Freeline Therapeutics Holdings plc (FRLN)

Source: https://www.quantisnow.com/company/FRLN
Generated: 2026-11-13T05:04:11.861Z

- Ticker: FRLN
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2020
- Website: freeline.life

## About

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

## Latest FRLN news and filings

- 2024-04-24 20:00 UTC [Freeline to Present New Data on its Gaucher and Parkinson's Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting](https://www.quantisnow.com/insight/freeline-to-present-new-data-on-its-gaucher-and-parkinsons-5429481)
- 2024-03-01 21:05 UTC [SEC Form 15-12G filed by Freeline Therapeutics Holdings plc](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-freeline-therapeutics-holdings-plc-5309593)
- 2024-02-26 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Freeline Therapeutics Holdings plc](https://www.quantisnow.com/insight/sec-form-effect-filed-by-freeline-therapeutics-holdings-plc-5289857)
- 2024-02-22 21:38 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Freeline Therapeutics Holdings plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-freeline-therapeutics-holdings-plc-5285326)
- 2024-02-22 21:36 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Freeline Therapeutics Holdings plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-freeline-therapeutics-holdings-plc-5285295)
- 2024-02-22 21:33 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Freeline Therapeutics Holdings plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-freeline-therapeutics-holdings-plc-5285221)
- 2024-02-22 21:32 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Freeline Therapeutics Holdings plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-freeline-therapeutics-holdings-plc-5285201)
- 2024-02-22 21:28 UTC [SEC Form POS AM filed by Freeline Therapeutics Holdings plc](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-freeline-therapeutics-holdings-plc-5285063)
- 2024-02-22 21:06 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Freeline Therapeutics Holdings plc (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-freeline-therapeutics-holdings-plc-5284491)
- 2024-02-20 20:22 UTC [SEC Form SC 13E3/A filed by Freeline Therapeutics Holdings plc (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13e3a-filed-by-freeline-therapeutics-holdings-plc-5274808)
- 2024-02-20 17:04 UTC [SEC Form 25-NSE filed by Freeline Therapeutics Holdings plc](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-freeline-therapeutics-holdings-plc-5274409)
- 2024-02-20 12:13 UTC [SEC Form 6-K] [SEC Form 6-K filed by Freeline Therapeutics Holdings plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-freeline-therapeutics-holdings-plc-5273197)
- 2024-02-20 12:00 UTC [Acquisition of Freeline by Syncona Becomes Effective](https://www.quantisnow.com/insight/acquisition-of-freeline-by-syncona-becomes-effective-5273056)
- 2024-02-14 17:15 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Freeline Therapeutics Holdings plc (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-freeline-therapeutics-holdings-plc-5261406)
- 2024-02-12 21:24 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Freeline Therapeutics Holdings plc (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-freeline-therapeutics-holdings-plc-5250526)
- 2024-02-12 21:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by Freeline Therapeutics Holdings plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-freeline-therapeutics-holdings-plc-5250043)
- 2024-02-12 17:00 UTC [Freeline Shareholders Approve Acquisition by Syncona](https://www.quantisnow.com/insight/freeline-shareholders-approve-acquisition-by-syncona-5249314)
- 2024-01-31 21:10 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Freeline Therapeutics Holdings plc (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-freeline-therapeutics-holdings-plc-5220470)
- 2024-01-18 21:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by Freeline Therapeutics Holdings plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-freeline-therapeutics-holdings-plc-5194175)
- 2024-01-17 21:17 UTC [SEC Form SC 13E3/A filed by Freeline Therapeutics Holdings plc (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13e3a-filed-by-freeline-therapeutics-holdings-plc-5191548)
- 2023-12-08 22:21 UTC [SEC Form SC 13E3 filed by Freeline Therapeutics Holdings plc](https://www.quantisnow.com/insight/sec-form-sc-13e3-filed-by-freeline-therapeutics-holdings-plc-5128212)
- 2023-12-01 13:56 UTC [SEC Form 6-K] [SEC Form 6-K filed by Freeline Therapeutics Holdings plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-freeline-therapeutics-holdings-plc-5112890)
- 2023-11-28 12:10 UTC [Market Chatter] [HC Wainwright & Co. Downgrades Freeline Therapeutics to Neutral, Lowers Price Target to $6.5](https://www.quantisnow.com/insight/hc-wainwright-co-downgrades-freeline-therapeutics-to-neutral-lowers-price-5105348)
- 2023-11-24 12:30 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Freeline Therapeutics Holdings plc (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-freeline-therapeutics-holdings-plc-5102271)
- 2023-11-22 16:42 UTC [Market Chatter] [Freeline Therapeutics shares are trading higher after the company announced it entered into a definitive agreement to be acquired by Syncona.](https://www.quantisnow.com/insight/freeline-therapeutics-shares-are-trading-higher-after-the-company-announced-5100628)
- 2023-11-22 14:48 UTC [Market Insight] [Gene Therapy Player Freeline Therapeutics Goes Private In $28M Deal](https://www.quantisnow.com/insight/gene-therapy-player-freeline-therapeutics-goes-private-in-28m-deal-5100431)
- 2023-11-22 14:20 UTC [SEC Form 6-K] [SEC Form 6-K filed by Freeline Therapeutics Holdings plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-freeline-therapeutics-holdings-plc-5100378)
- 2023-11-22 12:38 UTC [Market Insight] [Freeline Therapeutics ADS Shares To Resume Trade At 8:00 A.M. ET](https://www.quantisnow.com/insight/freeline-therapeutics-ads-shares-to-resume-trade-at-800-am-5100119)
- 2023-11-22 12:36 UTC [Market Chatter] [Syncona To Acquire Freeline Therapeutics for $28.3M](https://www.quantisnow.com/insight/syncona-to-acquire-freeline-therapeutics-for-283m-5100109)
- 2023-11-22 12:30 UTC [Public Offering] [Syncona to Acquire Freeline Therapeutics](https://www.quantisnow.com/insight/syncona-to-acquire-freeline-therapeutics-5100085)
- 2023-11-22 12:25 UTC [Market Insight] [Freeline Therapeutics Holdings Halted Pending News](https://www.quantisnow.com/insight/freeline-therapeutics-holdings-halted-pending-news-5100069)
- 2023-10-25 10:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by Freeline Therapeutics Holdings plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-freeline-therapeutics-holdings-plc-5036146)
- 2023-10-25 07:27 UTC [Market Chatter] [Freeline Presents New Data From Phase 1/2 GALILEO-1 Trial Of FLT201, Its Novel Gene Therapy Candidate, In Gaucher Disease](https://www.quantisnow.com/insight/freeline-presents-new-data-from-phase-12-galileo-1-trial-of-5036038)
- 2023-10-25 06:01 UTC [Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress](https://www.quantisnow.com/insight/freeline-presents-positive-new-data-from-phase-12-galileo-1-trial-5036015)
- 2023-10-18 21:00 UTC [Market Insight] [Where Freeline Therapeutics Stands With Analysts](https://www.quantisnow.com/insight/where-freeline-therapeutics-stands-with-analysts-5027088)
- 2023-10-18 18:15 UTC [Market Insight] [Why Nuvve Holding Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session](https://www.quantisnow.com/insight/why-nuvve-holding-shares-are-trading-lower-by-45-here-5026438)
- 2023-10-18 15:00 UTC [Market Insight] [Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023](https://www.quantisnow.com/insight/benzingas-top-ratings-upgrades-downgrades-for-october-18-2023-5026083)
- 2023-10-18 14:35 UTC [Market Chatter] [Wedbush Downgrades Freeline Therapeutics to Neutral, Lowers Price Target to $5](https://www.quantisnow.com/insight/wedbush-downgrades-freeline-therapeutics-to-neutral-lowers-price-target-to-5026021)
- 2023-10-18 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Freeline Therapeutics Holdings plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-freeline-therapeutics-holdings-plc-5025318)
- 2023-10-18 10:14 UTC [Market Insight] [Syncona Proposed To Acquire A;; Remaining Shares Of Freeline Therapeutics It Does Not Own For $5.00/ADS](https://www.quantisnow.com/insight/syncona-proposed-to-acquire-a-remaining-shares-of-freeline-therapeutics-5025221)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/FRLN
- Earnings history: https://www.quantisnow.com/earnings/FRLN
- Dividend history: https://www.quantisnow.com/dividends/FRLN
- Insider transactions: https://www.quantisnow.com/insiders/FRLN
- Options chain: https://www.quantisnow.com/options/FRLN
- SEC 8-K filings only: https://www.quantisnow.com/company/FRLN/8-k
- RSS and alerts for FRLN: https://www.quantisnow.com/docs/rss-feeds.md